Table 1.
Randomized study groups, doses, routes and time-points of different HIV-DNA priming (1st randomization) and HIV-MVA with or without CN54rgp140/GLA-AF boosting (2nd randomization) vaccinations.
Fig 1.
The number of individuals screened, randomized, allocated and withdrawn from the trial and the number of samples analyzed.
Table 2.
Frequency of ELISpot Responses Two Weeks after the 2nd MVA Alone or MVA Plus rgp140/GLA-AF Vaccination by First (Group I: 2x 0.1 mL ID [3mg/mL], Group II: 2x 0.1 mL ID + Electroporation [3mg/mL], Group III: 1x 0.1 mL ID + Electroporation [6mg/mL]) and Second (MVA Plus rgp140/GLA-AF or MVA Alone) Randomizations.
Fig 2.
(A) the DNA vaccine-specific Gag Smi peptide pool and, (B) the HIV-MVA vaccine-specific Gag CMDR, (C) Env CMDR peptide pools by the first randomization, to (D) Gag CMDR and (E) Env CMDR peptide pool stimulation by the second randomization in samples collected two weeks after the final vaccination in vaccine recipients only. Responders and non-responders are shown by filled and open circles, respectively. Median values in responders are given in brackets.
Fig 3.
(A) subtype B gp160, (B) subtype C gp140 and (C) subtype E gp120 antigen by the second randomization, in samples collected four weeks after the final vaccination in vaccine recipients only. Responders are shown by filled circles and non-responders are shown by open circles. The Wilcoxon rank-sum test was used for comparisons.
Table 3.
Frequency of antibody responses as determined by ELISA four weeks after the final vaccination.
Table 4.
Neutralizing Antibodies (NAb) determined four weeks after the final vaccination using the TZM-bl cell platform by second randomization.